SMNR
Semnur Pharmaceuticals, Inc.9.00
+0.00+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
2.07BP/E (TTM)
-Basic EPS (TTM)
-0.67Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
Merger with Semnur approved
Denali Capital Acquisition Corp. shareholders overwhelmingly approved the merger with Semnur Pharmaceuticals on September 3, 2025, alongside domestication from the Cayman Islands to Delaware and adoption of Semnur's name and governance structure. All proposals passed with near-unanimous support from 94% quorum turnout. The deal paves the way for Semnur's public debut. Post-merger board features biotech experts.
8-K
Denali secures $20M PIPE post-merger
Denali Capital Acquisition Corp. signed a securities purchase agreement on August 20, 2025, for a $20 million PIPE financing, issuing 1,250,000 shares of New Semnur common stock at $16.00 per share to JW Capital Securities Limited right after the pending merger with Semnur Pharmaceuticals. This bolsters the combined entity's cash position for operations, while Semnur commits to escrow 12,000,000 shares from parent Scilex Holding Company within 20 business days post-closing. Deal closes by December 31, 2025, or terminates. Risks include merger delays.
10-Q
Q2 FY2025 results
Denali Capital Acquisition Corp. posted a net loss of $385,122 for Q2 FY2025 ended June 30, 2025, up from net income of $448,912 a year earlier, as formation and operating costs climbed 123% y/y to $374,857 while trust income fell 97% y/y to $18,080 amid heavy redemptions. Q/q, the loss narrowed from $194,603 in Q1, with operating expenses edging up 10% but interest expense steady at $28,345. Liquidity tightened sharply, with cash outside trust dropping to $126 from $16,868 year-end and trust balance shrinking to $548,318 after $8.6 million in April redemptions, offset by $166,770 in sponsor loans pushing related-party debt to $1.59 million. The Semnur merger, valued at $2.5 billion in stock, advanced with a July amendment maintaining a 1.25-to-1 exchange ratio, yet Nasdaq delisting in April adds trading hurdles. Redemptions keep eroding the trust.
ADIL
Adial Pharmaceuticals, Inc
0.26-0.01
BSEM
BioStem Technologies, Inc.
3.84-0.11
CURX
Curanex Pharmaceuticals Inc
0.41-0.02
DRUG
Bright Minds Biosciences Inc.
93.99+8.32
LRMR
Larimar Therapeutics, Inc.
3.74-0.18
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
SCNX
Scienture Holdings, Inc.
0.55+0.00
SCPH
scPharmaceuticals Inc.
5.67+0.00
SMMT
Summit Therapeutics Inc.
17.23-0.15
TTNP
Titan Pharmaceuticals, Inc.
4.61-0.18